Longitudinal analysis of lung cancer using tissue and blood samples.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a longitudinal cohort of lung cancer patients by analyzing tissue and peripheral blood samples for metabolomics. It will focus on key treatment time points, including initial screening for lung nodules, postoperative evaluations, and therapeutic monitoring. The goal is to identify metabolic alterations that could serve as biomarkers for distinguishing between benign and malignant lung nodules, predicting treatment efficacy, and assessing long-term prognosis. By uncovering the underlying metabolic mechanisms, the study seeks to enhance personalized management of lung cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signing of the informed consent form;
2. Male or female, aged 18-75 years;
3. Patients with lung nodules confirmed by CT examination;
4. Good preoperative pulmonary function cooperation and complete reporting;
5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.

Exclusion Criteria:

1. Poor preoperative pulmonary function cooperation or missing reports;
2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
5. Coexisting with other severe functional impairments;
6. Patients with obstructive lesions such as airway or esophageal stenosis;

(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.

Where it's running

• the First Affiliated of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Jianxing He, Professer
• Email: drjiaxing.he@gmail.com
• Phone: 86-20-83337792

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Understanding what patients want from NSCLC treatment monitoring

  Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.

  Recruiting European Institute of Oncology · Milan, mI · NCT07909343

• Urine VOC Test to Detect Lung Cancer in Never Smokers

  A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07871656

• Barley and kefir to support gut health in active adults

  This study tests whether a daily barley and kefir meal for four weeks can change gut microbiota in physically active adults and whether those changes relate to certain metabolites in blood and urine.

  Recruiting Western Norway University of Applied Sciences · Bergen · NCT07864779

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.